Efficacy
death, SD, tumor
LUNG CANCER, DISEASE, SOLID TUMORS, TUMOR
The median follow‐up duration was 1.9 months (range, 1.3–4.3 months). According to the investigator assessment, partial response (PR) was achieved in two patients (7.7%), and stable disease (SD) was exhibited in one (3.8%), with no complete response (Table Overall efficacy of nivolumab maintenance therapy following platinum‐based chemotherapy.Abbreviations: CI, confidence interval; OS, overall survival; PFS, progression‐free survival; RECIST, response criteria in solid tumors.Waterfall plot of best change from baseline in 26 non‐small cell lung cancer patients.Progression‐free survival and overall survival of Kaplan–Meier curves of platinum‐based chemotherapy followed by nivolumab maintenance. (a) Progression‐free survival. (b) Overall survival.Comparison of baseline characteristics between patients in the responder and nonresponder groups in nivolumab maintenance therapy.Abbreviations: EGFR, epidermal growth factor receptor; PD‐L1, programmed death ligand 1; TMB, tumor mutation burden.